Skip to contentK
Kyntra Bio, Inc.
K
KYNBKyntra Bio, Inc. Q1 2022 · 10-Q
Revenue$60.83M$60.83M+58.3% vs Q1 2021 Net Income-$63.21M-$63.21MN/M vs Q1 2021 EPS Diluted-$0.68-$0.68N/M vs Q1 2021 Operating Income-$62,993,000N/M Operating Cash Flow
The same fiscal quarter, prior years. Thaler holds no estimates to compare against.
Kyntra Bio, Inc. · CIK 921299 · Engraved from SEC EDGAR
Free Cash Flowderived-$10,114,000N/M Margins · derivedOperating margin-103.6%+79.7 pt vs Q1 2021
Net margin-103.9%+82.8 pt vs Q1 2021
ended Mar 31, 2022 · filed May 9, 2022 · 39 d after period end